STARKSEMA
LIVE

Serial Number

97477233

Owner

Teva Pharmaceuticals USA

Attorney

Lori Wolfe

Filing Date

Jun 27, 2022

Add to watchlist:

No watchlists yet
View on USPTO

STARKSEMA Trademark

Serial Number: 97477233

STARKSEMA is a trademark filed by Teva Pharmaceuticals USA on June 27, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Teva Pharmaceuticals USA (12 trademarks)

400 Interpace Parkway
Parsippany, NJ 07054

Entity Type: 03

Trademark Details

Filing Date

June 27, 2022

Registration Date

Not Registered

Published for Opposition

August 1, 2023

Goods & Services

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment of auto-immune diseases; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives and hormone replacement therapy preparations, specifically, women's hormone replacement medications

Filing History

SOU EXTENSION RECEIVED WITH TEAS PETITION
Jun 10, 2026 TPEX
NOTICE OF REVIVAL - E-MAILED
Jun 10, 2026 NREV
PETITION TO REVIVE-GRANTED
Jun 10, 2026 PETG
TEAS PETITION TO REVIVE RECEIVED
Jun 10, 2026 PROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 19, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 19, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 19, 2026 REAP
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 27, 2026 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 27, 2026 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 17, 2025 EXRA
SOU EXTENSION 4 GRANTED
Sep 16, 2025 EX4G
SOU EXTENSION 4 FILED
Sep 16, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Sep 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 27, 2025 EXRA
SOU EXTENSION 3 GRANTED
Mar 26, 2025 EX3G
SOU EXTENSION 3 FILED
Mar 26, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 26, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 14, 2024 EXRA
SOU EXTENSION 2 GRANTED
Aug 14, 2024 EX2G
SOU EXTENSION 2 FILED
Aug 14, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 14, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 15, 2024 EXRA
SOU EXTENSION 1 GRANTED
Mar 14, 2024 EX1G
SOU EXTENSION 1 FILED
Mar 14, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 14, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 26, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 1, 2023 NPUB
PUBLISHED FOR OPPOSITION
Aug 1, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 12, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 23, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 16, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 15, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 15, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 19, 2023 GNRN
NON-FINAL ACTION E-MAILED
Apr 19, 2023 GNRT
NON-FINAL ACTION WRITTEN
Apr 19, 2023 CNRT
ASSIGNED TO EXAMINER
Apr 11, 2023 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 22, 2023 TCCA
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Feb 22, 2023 EWAF
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 22, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 22, 2023 REAP
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 14, 2022 NWOS
NEW APPLICATION ENTERED
Jun 30, 2022 NWAP